MXPA02010405A - Derivados de aminocarboxialquilo novedosos de acido barbiturico. - Google Patents
Derivados de aminocarboxialquilo novedosos de acido barbiturico.Info
- Publication number
- MXPA02010405A MXPA02010405A MXPA02010405A MXPA02010405A MXPA02010405A MX PA02010405 A MXPA02010405 A MX PA02010405A MX PA02010405 A MXPA02010405 A MX PA02010405A MX PA02010405 A MXPA02010405 A MX PA02010405A MX PA02010405 A MXPA02010405 A MX PA02010405A
- Authority
- MX
- Mexico
- Prior art keywords
- barbituric acid
- alkyl derivatives
- novel amino
- carboxy alkyl
- amino carboxy
- Prior art date
Links
- -1 amino carboxy Chemical group 0.000 title abstract 2
- 150000007656 barbituric acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/66—Thiobarbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a derivados novedosos de amino carboxi alquilo terapeuticamente activos de acido barbiturico de formula (ver formula I) en donde por lo menos uno de R1, R2, R3 o R4 comprende una porcion. NH2 y por lo menos uno de R1, R2, R3 o R4 comprende una porcion COOH; se provee tambien un metodo para preparar compuestos de formula I y composiciones farmaceuticas que comprenden los compuestos; los compuestos novedosos actuan como moduladores de receptores de glutamato metabotropicos y, como tales, son utiles en el tratamiento de enfermedades del sistema nervioso central relacionadas con el sistema de receptores de glutamato metabotropicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002306170A CA2306170A1 (en) | 2000-04-18 | 2000-04-18 | Novel amino, carboxy derivatives of barbituric acid |
PCT/CA2001/000503 WO2001079185A1 (en) | 2000-04-18 | 2001-04-18 | Novel amino carboxy alkyl derivatives of barbituric acid |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02010405A true MXPA02010405A (es) | 2004-09-06 |
Family
ID=4165956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02010405A MXPA02010405A (es) | 2000-04-18 | 2001-04-18 | Derivados de aminocarboxialquilo novedosos de acido barbiturico. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030199533A1 (es) |
EP (1) | EP1276727A1 (es) |
AU (1) | AU2001248197A1 (es) |
CA (1) | CA2306170A1 (es) |
MX (1) | MXPA02010405A (es) |
NZ (1) | NZ522195A (es) |
WO (1) | WO2001079185A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
US6939873B2 (en) | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
CN1896084A (zh) * | 2002-01-30 | 2007-01-17 | 塔罗制药工业有限公司 | 非镇静性巴比土酸衍生物 |
BR0317289A (pt) | 2002-12-11 | 2005-11-08 | Taro Pharma Ind | Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico |
JP2007513170A (ja) * | 2003-12-04 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | スルホン置換イミダゾ環エーテル |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
KR101027480B1 (ko) * | 2006-01-04 | 2011-04-06 | 삼성전자주식회사 | 통신 시스템에서 데이터 송수신 방법 및 시스템 |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20230416231A1 (en) * | 2022-02-25 | 2023-12-28 | Southern Research Institute | Uracil Derivatives for Stimulating Read-Through of Premature Termination Codons |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS176667B1 (es) * | 1975-02-17 | 1977-06-30 | ||
IL69722A (en) * | 1983-09-14 | 1986-09-30 | Taro Pharma Ind | Oxopyrimidine derivatives and pharmaceutical compositions containing them |
US4714838A (en) * | 1986-10-31 | 1987-12-22 | Minnesota Mining And Manufacturing Company | Second harmonic generation with N,N'-substituted barbituric acids |
GB9325368D0 (en) * | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
US5959109A (en) * | 1996-05-15 | 1999-09-28 | Neurocrine Biosciences, Inc. | Compounds and methods for increasing endogenous levels of corticotropin-releasing factor |
-
2000
- 2000-04-18 CA CA002306170A patent/CA2306170A1/en not_active Abandoned
-
2001
- 2001-04-18 WO PCT/CA2001/000503 patent/WO2001079185A1/en not_active Application Discontinuation
- 2001-04-18 MX MXPA02010405A patent/MXPA02010405A/es unknown
- 2001-04-18 US US10/258,200 patent/US20030199533A1/en not_active Abandoned
- 2001-04-18 AU AU2001248197A patent/AU2001248197A1/en not_active Abandoned
- 2001-04-18 EP EP01921083A patent/EP1276727A1/en not_active Withdrawn
- 2001-04-18 NZ NZ522195A patent/NZ522195A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20030199533A1 (en) | 2003-10-23 |
NZ522195A (en) | 2004-12-24 |
EP1276727A1 (en) | 2003-01-22 |
AU2001248197A1 (en) | 2001-10-30 |
CA2306170A1 (en) | 2001-10-18 |
WO2001079185A1 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02010405A (es) | Derivados de aminocarboxialquilo novedosos de acido barbiturico. | |
ATE265419T1 (de) | Spiro(2.4)heptanaminocarbonsäure und ihre derivate | |
MXPA02001340A (es) | Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos. | |
GEP19991870B (en) | Alkyl Amine Derivatives of Substituted Quinoxaline 2,3-Diones as Glutamate Receptor Antagonists | |
UA44254C2 (uk) | Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція | |
CA2401229A1 (en) | Aryl fused azapolycyclic compounds | |
JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
FR2743562B1 (fr) | Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant | |
NO963850D0 (no) | Heterosykliske forbindelser, deres fremstilling og anvendelse | |
AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
BR9910130A (pt) | Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação | |
GR3036639T3 (en) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist | |
DE69611728D1 (de) | N-(4-substituerte benzyl)-2-aminolactamderivate | |
IL125982A0 (en) | 2-(arylphenyl) amino-imidazoline derivatives | |
MXPA02000242A (es) | Analogos de 2-aminoindano. | |
AU1466295A (en) | Amino acid derivatives and their use as phospholipase a2 inhibitors | |
GEP19991869B (en) | Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists | |
AU5644296A (en) | Novel heterocyclic chemistry | |
WO2001002340A3 (en) | Novel aminoindanes | |
DK1003749T3 (da) | 8-Substituerede-9H-1,3dioxolo/4,5-h/2,3-benzodiazepinderivater som ampa/kainat-receptor-hæmmere | |
HK1040237A1 (en) | Fused polycyclic amino acids as pharmaceutical agents. | |
HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AU5398300A (en) | Excitatory amino acid receptor modulators | |
YU38498A (sh) | Derivati 2-(arilfenil)amino-imidazolina |